Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jae Jung

Physical Medicine & Rehabilitation Los Angeles, CA Medical Doctor

NPI 1184810707 CMS profile 281019

100 Ucla Medical Plz, Suite 755, Los Angeles, CA 90024

Open in the dashboard

General payments

$34,114

472 records reported · program years 2019–2025

Research payments

$230

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jae Jung of Los Angeles, CA is reported in the CMS Open Payments database as having received $34,114 across 472 general payments and $230 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,929 77
2024 General $5,955 82
2023 General $5,917 84
2022 General $4,967 65
2021 General $3,117 53
2020 General $2,750 41
2020 Research $230 1
2019 General $5,480 70

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jae Jung
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jae Jung were reported at $5,929. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jae Jung Physical Medicine & Rehabilitation median Middle half National median
2019 $5,480 $133 $45–$390 $163
2020 $2,750 $88 $29–$272 $114
2021 $3,117 $116 $33–$360 $132
2022 $4,967 $123 $40–$378 $149
2023 $5,917 $131 $43–$396 $160
2024 $5,955 $141 $45–$409 $164
2025 $5,929 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,033 164 payments
  2. Medtronic, Inc. $7,809 115 payments
  3. SPR Therapeutics, Inc $2,551 32 payments
  4. Abbott Laboratories $2,538 25 payments
  5. Vertiflex, Inc. $2,031 16 payments
  6. Medtronic USA, Inc. $1,721 27 payments
  7. Nevro Corp. $1,064 13 payments
  8. Nalu Medical, Inc. $895 11 payments
  9. Stryker Corporation $875 12 payments
  10. Integra LifeSciences Corporation $718 6 payments
  11. Other $3,879 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $32,008 466 payments
  2. Travel and Lodging $1,135 3 payments
  3. Education $512 2 payments
  4. Consulting Fee $460 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $6,168 88 payments
  2. SPRINT PNS System $2,551 32 payments
  3. Superion ISS $2,031 16 payments
  4. WaveWriter Alpha Prime 16 $1,896 37 payments
  5. General - Pain Management $1,718 24 payments
  6. Proclaim Family of SCS IPGs $1,338 13 payments
  7. GENERAL PAIN MANAGEMENT $1,128 24 payments
  8. Senza $925 12 payments
  9. Nalu Neurostimulation System $895 11 payments
  10. RESTORE $759 15 payments
  11. Other $13,545 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $230 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

75

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$642

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 42 $461
Meloxicam Generic 33 $181

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$131,822

Medicare's payments for the services billed

Medicare patients

414

Average age 74

Services billed

1,400

250 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Ischemic heart disease 32%
Depression 30%
Osteoporosis 30%
Diabetes 29%
Chronic kidney disease 17%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

473 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record